A randomized controlled pilot trial of etanercept and alpha-1 antitrypsin to improve autologous islet engraftment.

ABSTRACT:

Background

In total pancreatectomy with islet auto-transplantation, successful diabetes outcomes are limited by islet loss from the instant blood mediated inflammatory response. We hypothesized that blockade of the inflammatory response with either etanercept or alpha-1-antitrypsin would improve islet function and insulin independence.

Methods

We randomized 43 participants to receive A1AT (90 mg/kg x 6 doses, n = 13), or etanercept (50 mg then 25 mg x 5 doses, n = 14), or standard care (n = 16), aiming to reduce detrimental effects of innate inflammation on early islet survival. Islet graft function was assessed using mixed meal tolerance testing, intravenous glucose tolerance testing, glucose-potentiated arginine-induced insulin secretion studies, HbA1c, and insulin dose 3

SUBMITTER: Abdel-Karim TR 

PROVIDER: S-EPMC9839597 | biostudies-literature | 2023 Jan

REPOSITORIES: biostudies-literature